New Autoimmune Disease Treatment Options Reach Patients

FDA approved IMAAVY (nipocalimab) for warm autoimmune hemolytic anemia after randomized ENERGY data showed more durable hemoglobin improvement and less fatigue than placebo. Emerging cellular approaches, including AlloNK plus rituximab in a small uncontrolled Sjögren’s study, remain investigational and require longer-term safety, durability, and comparative evidence.